Product Description
Mechanisms of Action: HCV-NS5B Inhibitor,NN Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hepatitis A|Hepatitis C
Phase 1: Healthy Volunteers|Hepatic Insufficiency|Hepatitis C|Liver Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
3173A1-200 | P2 |
Completed |
Hepatitis A|Hepatitis C |
2008-07-01 |
|
3173A1-105 | P1 |
Completed |
Liver Failure|Hepatitis C|Hepatic Insufficiency |
2007-10-01 |
|
3173A1-1120 | P1 |
Completed |
Healthy Volunteers |
2007-08-01 |
|
3173A1-112 | P1 |
Completed |
Healthy Volunteers |
2007-06-01 |